trifluoromethanesulfonic acid 2,3-dichloro-4-formylphenyl ester | 280752-96-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: trifluoromethanesulfonic acid 2,3-dichloro-4-formylphenyl ester
• 英文别名: 4-trifluoromethanesulfonyloxy-2,3-dichlorobenzaldehyde；trifluoro-methanesulfonic acid 2,3-dichloro-4-formyl-phenyl ester；2,3-dichloro-4-trifluoromethanesulfonyloxy-benzaldehyde；2,3-dichloro-4-formylphenyl trifluoromethanesulfonate；(2,3-dichloro-4-formylphenyl) trifluoromethanesulfonate
• CAS: 280752-96-7
• 化学式: C₈H₃Cl₂F₃O₄S
• 分子量: 323.077
• InChiKey: OPKLTIADNGGTQD-UHFFFAOYSA-N

物化性质

• 熔点：
  44-45 °C
• 沸点：
  367.9±42.0 °C(Predicted)
• 密度：
  1.732±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  68.8
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  trifluoromethanesulfonic acid 2,3-dichloro-4-formylphenyl ester 在 四(三苯基膦)钯 三溴化硼 、 sodium carbonate 作用下， 以 乙二醇二甲醚 、 二氯甲烷 、 水 为溶剂， 反应 3.5h， 生成 2',3'-dichloro-4'-(dibromomethyl)-3-fluorobiphenyl-4-ol
  参考文献：
  名称：

  ERβ Ligands. Part 2: Synthesis and structure–activity relationships of a series of 4-hydroxy-biphenyl-carbaldehyde oxime derivatives

  摘要：

  A series of biphenyl carbaldehyde oximes (6) was prepared and shown to have significant selectivity for the estrogen receptor-beta (ERbeta). The exploitation of the oxime moiety as a hydrogen bond donating group, which mimicked the C-ring of genistein makes these compounds unique. Molecular modeling studies showed the oxime moiety hydrogen bonding to the histidine residue, which was supported by the structure-activity relationships. The most potent compounds in this study had IC50 values in a radio-liaand binding assay of between 8-35 nM. Among the most selective compounds were 6i and 6s (49- and 31-fold ERbeta selective, respectively). (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2004.03.028
• 作为产物：
  描述：

  2,3-二氯茴香醚 在 吡啶 、 三溴化硼 、 四氯化钛 作用下， 以 二氯甲烷 为溶剂， 反应 5.0h， 生成 trifluoromethanesulfonic acid 2,3-dichloro-4-formylphenyl ester
  参考文献：
  名称：

  ERβ Ligands. Part 2: Synthesis and structure–activity relationships of a series of 4-hydroxy-biphenyl-carbaldehyde oxime derivatives

  摘要：

  A series of biphenyl carbaldehyde oximes (6) was prepared and shown to have significant selectivity for the estrogen receptor-beta (ERbeta). The exploitation of the oxime moiety as a hydrogen bond donating group, which mimicked the C-ring of genistein makes these compounds unique. Molecular modeling studies showed the oxime moiety hydrogen bonding to the histidine residue, which was supported by the structure-activity relationships. The most potent compounds in this study had IC50 values in a radio-liaand binding assay of between 8-35 nM. Among the most selective compounds were 6i and 6s (49- and 31-fold ERbeta selective, respectively). (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2004.03.028

文献信息

• Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds
  申请人：Abbott Laboratories

  公开号：US20040116518A1

  公开（公告）日：2004-06-17

  The present invention relates to novel cinnamide compounds that are useful for treating inflammatory and immune diseases and cerebral vasospasm, to pharmaceutical compositions containing these compounds, and to methods of inhibiting inflammation or suppressing immune response in a mammal.

  本发明涉及新型肉桂酰胺化合物，用于治疗炎症和免疫性疾病以及脑血管痉挛，以及含有这些化合物的药物组合物，以及在哺乳动物中抑制炎症或抑制免疫反应的方法。
• Amino(oxo) acetic acid protein tyrosine phosphatase inhibitors
  申请人：——

  公开号：US20020035136A1

  公开（公告）日：2002-03-21

  Compounds of formula (I) 1 or therapeutically acceptable salts thereof, are protein tyrosine kinase PTP1B inhibitors. Preparation of the compounds, compositions containing the compounds, and treatment of diseases using the compounds are disclosed.

  式(I)1的化合物或其治疗上可接受的盐是蛋白酪氨酸激酶PTP1B抑制剂。公开了该化合物的制备、含有该化合物的组合物以及使用该化合物治疗疾病的方法。
• [EN] CELL ADHESION-INHIBITING ANTIINFLAMMATORY AND IMMUNE-SUPPRESSIVE COMPOUNDS<br/>[FR] COMPOSES INHIBITEUR DE L'ADHESION CELLULAIRE, ANTI-INFLAMMATOIRES ET IMMUNOSUPPRESSEURS
  申请人：ABBOTT LAB

  公开号：WO2000059880A1

  公开（公告）日：2000-10-12

  The present invention relates to cinnamide compounds of formula (I), in which at least one of R1 to R5 is a 'cis-cinnamide' (a) or a 'trans-cinnamide' (b) and the other variables are as defined in the claims, that are useful for treating inflammatory and immune diseases, to pharmaceutical compositions containing these compounds and to methods of inhibiting inflammation or suppressing immune response in a mammal.

  本发明涉及一种公式(I)的肉桂酰胺化合物，其中R1到R5中至少有一个是“顺式肉桂酰胺”(a)或“反式肉桂酰胺”(b)，其他变量如权利要求所定义，该化合物对治疗炎症和免疫性疾病有用，对含有这些化合物的制药组合物以及在哺乳动物中抑制炎症或抑制免疫反应的方法。
• Hydroxy-biphenyl-carbaldehyde oxime derivatives and their use as estrogenic agents
  申请人：Mewshaw Eric Richard

  公开号：US20050020676A1

  公开（公告）日：2005-01-27

  This invention provides estrogen receptor modulators having the structure: wherein R 1 to R 6 and R 8 are as defined in the specification; or a pharmaceutically acceptable salt thereof.

  本发明提供了具有以下结构的雌激素受体调节剂：其中R1至R6和R8的定义如规范中所述；或其药学上可接受的盐。
• Hydroxy-Biphenyl-Carbaldehyde Oxime Derivatives and Their Use As Estrogenic Agents
  申请人：Mewshaw Eric Richard

  公开号：US20080033049A1

  公开（公告）日：2008-02-07

  This invention provides estrogen receptor modulators having the structure: wherein R 1 to R 6 and R 8 are as defined in the specification; or a pharmaceutically acceptable salt thereof.

  该发明提供了具有以下结构的雌激素受体调节剂：其中R1至R6和R8如规范中定义；或其药用盐。